METADATA
last updated: 2026-02-20 RT initial creation
file_name: _AI_RADx Program Overview - NIH Rapid Acceleration of Diagnostics.md
file_date: 2026-02-20
title: RADx Program Overview - NIH Rapid Acceleration of Diagnostics
category: various
subcategory: external-programs-reports
tags: 
source_file_type: md
xfile_type: NA
gfile_url: https://docs.google.com/document/d/13X6tcUSaSfGbyhfCm6BDQK9HW27khP3Ung6iUe5d67k
xfile_github_download_url: https://raw.githubusercontent.com/FocusOnFoundationsNonprofit/floodlamp-archive/main/various/external-programs-reports/RADx%20Program%20Overview%20-%20NIH%20Rapid%20Acceleration%20of%20Diagnostics.md
pdf_gdrive_url: NA
pdf_github_url: NA
conversion_input_file_type: NA
conversion: NA
license: CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/
tokens: 2429
words: 1571
notes: Created by Claude Opus 4.6 Max during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** AI-generated overview of the NIH RADx initiative combining information from FloodLAMP archive documents with public web sources (NIH, NIBIB, PMC). Source archive documents include: RADx 2020 Submitted Proposal, RADx 2022 Solicitation, RADx 2022 Submitted Proposal, and 2024-03-01 RADx Tech Report on COVID-19 Diagnostic Technologies. Web sources include NIH RADx program pages, NIBIB RADx Tech timeline, and NIH Director's Blog.
summary_short: An overview of the NIH Rapid Acceleration of Diagnostics (RADx) initiative, covering its $1.5 billion congressional appropriation, four program arms (RADx Tech, RADx-UP, RADx-rad, RADx ATP), milestone-driven innovation funnel structure, key accomplishments including 55 FDA EUAs and 7.8 billion tests of U.S. capacity, and ongoing expansion beyond COVID-19 into multiplex respiratory diagnostics and other public health applications.


CONTENT

## Prompt (Verbatim)
Okay, so here provide a general summary of what RADx was and just have this only be a paragraph. Kind of how long they operated, what agency they were under, and how much funding.

Oh, I meant for you not to just draw from the archive, but overall you can search the web.

Yes - Go ahead and do that search and create the updated information. You know, it can be longer than a paragraph and I think it's going to be better to do some of it as bullet points and structure it in Markdown and start with heading level two, not heading level one. And I think I'm going to pull out the Rad-X stuff and do it as a separate file or a couple of files. It's because it's so important. So for now, in this processed commentary, I'm just going to leave a placeholder for this as a work in progress.

## Prompt (Cleaned)
Provide a general summary of what the NIH RADx program was, structured in markdown with level-two headings. Cover how long it operated, what agency it was under, how much funding it received, and its key accomplishments. Search the web for comprehensive public information in addition to drawing from FloodLAMP archive documents. Use bullet points and structured formatting rather than a single paragraph. This will be saved as a standalone reference file in the archive because the RADx program is important enough to warrant dedicated coverage.

**Files included in context window:**
- _context-commentary_various-fl-proposals_INITIAL.md
- prompt_context-commentary_interview.md
- RADx 2020 Submitted Proposal - FloodLAMP (Aug 2020 - 1M - Not Funded).md
- RADx 2022 Solicitation - High-Performance COVID-19 Rapid Tests (Oct 2022).md
- RADx 2022 Submitted Proposal - FloodLAMP (Oct 2022 - 3M - Not Funded).md
- 2024-03-01_RADx Tech Report on COVID-19 Diagnostic Technologies.md
- prompt_save-ai-response-to-archive-md.md
- Waste Disposal and Risk Assessment.md


## RADx Program Overview

The Rapid Acceleration of Diagnostics (RADx) initiative was launched by the National Institutes of Health (NIH) on April 29, 2020, just five days after Congress appropriated $1.5 billion to NIH for SARS-CoV-2 testing through the Paycheck Protection Program and Health Care Enhancement Act (signed April 24, 2020). The initiative was created to dramatically accelerate the development, validation, and commercialization of COVID-19 diagnostic testing technologies, compressing development timelines from years to months. Funding support later transitioned to the American Rescue Plan Act of 2021.

RADx was led by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), operating in collaboration with the NIH Office of the Director (OD). The program leveraged the existing NIBIB Point-of-Care Technologies Research Network (POCTRN) infrastructure and coordinated closely with the FDA, CDC, BARDA, ASPR, and the Department of Defense. Approximately 900 collaborators from government, academia, and the private sector participated in the RADx Tech network.


## Four RADx Programs

The RADx initiative comprised four distinct programs:

### RADx Tech
The flagship technology development arm, focused on speeding the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improved clinical laboratory tests. RADx Tech used a competitive, milestone-driven "innovation funnel" that matched test developers with teams of technical, business, manufacturing, and regulatory experts. The first solicitation offered up to $500 million across all phases of development. Three separate solicitation rounds were conducted:

- **RADx Tech I (2020)**: Initial call for rapid COVID-19 testing technologies. Received 716 applications before the portal closed in August 2020. Within the first 24 hours alone, 400 proposals were submitted.
- **RADx Tech II (2021)**: Focused on advanced-readiness technologies including multiplex tests, tests with PCR-comparable performance, and variant-detecting tests. Only considered technologies that could reach market in 2021.
- **RADx Tech III (2022)**: Two sub-solicitations -- one for accessible OTC tests usable by persons with disabilities, and one for high-performance OTC/POC tests with universal design features and performance approaching or exceeding lab-based tests. Funded 25 Work Package 1 projects.

### RADx-UP (Underserved Populations)
Focused on understanding and reducing COVID-19 testing disparities in vulnerable and underserved populations, including racial and ethnic minorities, residents of nursing homes and correctional facilities, rural communities, underserved urban populations, pregnant women, and people experiencing homelessness. RADx-UP established clinical research sites across the country and collaborated with community organizations such as tribal health centers, houses of worship, and homeless shelters. The program supported 142 awarded projects.

### RADx-rad (Radical)
Supported non-traditional, "outside-the-box" approaches to COVID-19 testing and surveillance. The program awarded over $107 million to fund 49 research projects across 43 U.S. institutions. Focus areas included:

- Non-traditional viral screening using biological or physiological markers
- Novel analytical platforms with new chemistries or engineering approaches
- Wastewater detection methods for community-level surveillance
- AI-integrated diagnostic systems
- Breath-based and airborne detection biosensors
- Smell and taste function tests as infection indicators

### RADx ATP (Advanced Technology Platforms)
Supported late-stage development of innovative point-of-care and home-based tests along with improved clinical laboratory tests to increase U.S. testing capacity.

Additionally, the **Independent Test Assessment Program (ITAP)** was launched in collaboration with the FDA to accelerate authorization of tests produced outside the U.S. ITAP independently conducted analytical and clinical validation according to FDA-agreed protocols, allowing the FDA to authorize new tests in a matter of days after data submission. ITAP accounted for approximately half of the increased testing capacity in the U.S.


## Innovation Funnel Structure

The RADx Tech innovation funnel used a stage-gated process to maximize efficiency:

- **Rolling Review**: Proposals evaluated by external expert panels on technical, clinical, regulatory, and commercial feasibility.
- **Deep Dive**: Selected projects underwent a two-week intensive examination by RADx Tech experts to identify risks and develop milestone-driven work plans.
- **Work Package 1 (De-Risking)**: Addressed high-risk barriers to success. Milestone-driven funding with close NIBIB monitoring.
- **Work Package 2 (Implementation)**: Full range of activities for FDA authorization, manufacturing, and commercialization. Funding contingent on WP1 milestone achievement and market competitiveness.

Initial Phase 2 contract awards in 2020:

| Date | Amount | Contracts |
| --- | --- | --- |
| July 31, 2020 | $248.7 million | 7 contracts |
| September 2, 2020 | $129.3 million | 9 contracts |
| October 6, 2020 | $98.4 million | 6 contracts |
| | | |


## Key Accomplishments

As reported in the March 2024 RADx Tech program report:

- Evaluated over 1,000 proposals from 47 states/territories and 23 countries
- Funded over 250 organizations to develop diagnostic technologies
- 242 applications (15-20% of total) underwent in-depth review by RADx expert teams
- 68 projects received funding for de-risking and validation
- 50 projects received funding for authorization and deployment
- Produced 55 FDA Emergency Use Authorization tests
- U.S. capacity exceeding 7.8 billion tests and test products
- First-ever EUA for a COVID-19 OTC diagnostic test (December 2020)
- 18 FDA-authorized OTC COVID-19 tests
- 12 OTC COVID-19 devices authorized through ITAP
- A POC test received an EUA within 10 weeks of program launch
- 125 publications by RADx Tech members and collaborators
- First EUA granted for a test aligned with accessibility design principles
- Best-practice guidelines for accessible test design published June 20, 2023

Monthly U.S. test production scaled rapidly in 2020: from over 16 million in September to over 24 million in December. By February 2022, U.S. testing capacity reached over 1.2 billion tests monthly, with more than 85% being rapid home or point-of-care tests -- compared to fewer than 8 million tests performed in April 2020.


## Community Programs and Distribution

RADx Tech established several programs beyond direct test development:

- **RADx MARS (Mobile At-Home Reporting through Standards)**: Standardized how self-reported home test results are collected and transmitted to state, federal, and local health systems.
- **Make My Test Count**: Website for self-reporting home test results, launched November 2022, replacing manufacturer apps with a single reporting pathway. Supported all FDA-authorized OTC COVID-19 and COVID-19/Flu multiplex tests.
- **Say Yes! COVID Test (SYCT)**: Cooperative effort with state and local health departments, NIH, and CDC that distributed over 2 million free home tests in select communities. Demonstrated that home testing can impact behavior and reduce community transmission. Lessons learned enabled the covidtests.gov nationwide free test distribution.
- **Home Test-to-Treat**: Virtual community health intervention providing free COVID-19 tests, telehealth consultations, and treatments to eligible individuals at home. Later expanded to include influenza testing and treatment.
- **COVID-19 Test Accessibility Program**: Partnership with HHS agencies and disability advocates to develop and publish best-practices for universally accessible test design, hosted on the U.S. Access Board website.


## Ongoing Operations and Expansion

As of the March 2024 program report, RADx Tech continues to operate and has expanded beyond COVID-19. The RADx infrastructure is being leveraged for:

- Multiplex home and POC diagnostic products for COVID-19, Flu, and RSV
- POC multiplex tests for lesion-presenting diseases including Mpox, HSV1/2, VZV, and Syphilis
- POC test for Hepatitis C to support a U.S. elimination program
- Fetal Monitoring Challenge to reduce fetal mortality
- Blueprint MedTech for medical devices addressing pain and nervous system diseases
- Maternal Health Challenge for devices to reduce maternal mortality in underserved settings
- Advanced Platforms for HIV Viral Load Testing at the POC


## Sources
- NIH RADx program pages: https://www.nih.gov/research-training/medical-research-initiatives/radx
- NIBIB RADx Tech timeline: https://www.nibib.nih.gov/covid-19/radx-tech-program/radx-tech-timeline
- NIBIB RADx Tech program: https://www.nibib.nih.gov/programs/radx-tech-program
- RADx Tech March 2024 White Paper: https://www.nih.gov/sites/default/files/research-training/initiatives/radx/RADx-Tech-White-Paper-March-2024.pdf
- NIH news release on RADx-rad: https://www.nih.gov/news-events/news-releases/nih-support-radical-approaches-nationwide-covid-19-testing-surveillance
- PMC article "Radical solutions": https://pmc.ncbi.nlm.nih.gov/articles/PMC8023346/
- FloodLAMP archive: 2024-03-01_RADx Tech Report on COVID-19 Diagnostic Technologies.md